Scientists map tumor immune cells

recently, two separate
published in the Journal of Technology painted a detailed picture of immune cells surrounding tumors. One of the research groups, scientists from institutions such as the University of Zurich in Switzerland, studied kidney cancer. It was found that tumors with different clinical results had unique immune cell maps. These maps can also estimate the prognostic prognosticity of a cancer patient. A team from the United States studied lung cancer. It was found that early tumors disrupted the activity of immune cells. The findings are expected to help develop more accurate cancer immunotherapy.
" we found that immune cells begin to become dysfunctional at a very early stage of tumor formation. However, cancer immunotherapy is usually used only when the patient has relapsed and the cancer is advanced. We want to advocate for the use of immunotherapy at an earlier stage of cancer so that it is not too late. Miriam Merad, a lung cancer scientist at Mount Sinai Medical School and co-author of the study, said. Bernd Bodenmiller, an expert in kidney cancer at the University of Zurich, says understanding the differences in immune cells between tumors in different patients offers greater possibilities for developing personalized immunotherapy.
tumor's unsuppressed growth ability is due to its recruitment of immune cells. They form micro-ecosystems. In this system, the relationship between cells and cells is not seen in normal tissues. The new immune cell map reveals these ecosystems.
two studies, scientists tagged individual immune cells around tumors with 30 to 40 antibodies. Using this information, scientists use a detector to screen cells and reveal their "identities" and whether they are functional or defective.
Bodenmiller team surveyed tumor samples from 73 patients with renal cell carcinoma. The results showed that the number of T-cells and macrophages in them was more variable than previously thought. The team also found that some patients with specific combinations of T-cells and macrophages tended to develop rapidly developing cancers.
and Others surveyed tumor samples and normal tissue in 28 patients with early or late-stage pulmonary adenocarcinoma. They observed changes in cell behavior much earlier than expected. Stage I tumors have shown a large number of inhibitory macrophages and T-cells aggregation, as well as NIK cell loss. These tumors are usually surgically removed, and although they have a good prognosis, 25% of patients still relapse